Meeting
2014 ASCO Annual Meeting
Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial.
Authors
Volker Heinemann
Department of Medical Oncology, Klinikum Grosshadern, University of Munich, Munich, Germany
Volker Heinemann , Dominik Paul Modest , Ludwig Fischer von Weikersthal , Thomas Decker , Alexander Kiani , Ursula Vehling-Kaiser , Salah-Eddin Al-Batran , Tobias Heintges , Christian A. Lerchenmuller , Christoph Kahl , Gernot Seipelt , Frank Kullmann , Martina Stauch , Werner Scheithauer , Swantje Held , Clemens Albrecht Giessen , Andreas Jung , Thomas Kirchner , Sebastian Stintzing
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 3600)
DOI
10.1200/jco.2014.32.15_suppl.3600
Abstract #
3600
Poster Bd #
63
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Randomized study to investigate a switch maintenance concept with 5-FU plus bevacizumab after FOLFIRI plus cetuximab induction treatment versus continued treatment with FOLFIRI plus cetuximab: Report of a secondary endpoint of the phase-III FIRE-4 study (AIO KRK-0114).
First Author: Sebastian Stintzing
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Predictive factors for renal function deterioration during palliative first-line chemotherapy for metastatic colorectal cancer.
First Author: AhReum Lim
Poster
2017 ASCO Annual Meeting
Genetic polymorphisms of CCL5 and CCR5 to predict efficacy of cetuximab-based treatment in metastatic colorectal cancer patients depending on primary tumor location.
First Author: Mitsukuni Suenaga
Poster
2015 ASCO Annual Meeting
Genetic variants of kinases suppressors of Ras (KSR) to predict tumor response to first-line cetuximab in patients with mCRC: Prospective analysis in the FIRE 3 trial.
First Author: Leonor Benhaim